Concentration–QTc Modeling to Support Clinical Development of Fezolinetant
Fuente:
Wiley Open Access
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2025
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1867011435069964288 |
|---|---|
| author | Jace C. Nielsen Masako Saito Xuegong Wang Megumi Iwai Graeme L. Fraser Steven Ramael Jiayin Huang |
| author_facet | Jace C. Nielsen Masako Saito Xuegong Wang Megumi Iwai Graeme L. Fraser Steven Ramael Jiayin Huang Jace C. Nielsen Masako Saito Xuegong Wang Megumi Iwai Graeme L. Fraser Steven Ramael Jiayin Huang |
| collection | Wiley Open Access |
| contents | Concentration–QTc Modeling to Support Clinical Development of Fezolinetant Jace C. Nielsen Masako Saito Xuegong Wang Megumi Iwai Graeme L. Fraser Steven Ramael Jiayin Huang Clinical Pharmacology in Drug Development Abstract Fezolinetant is a non‐hormonal, selective neurokinin‐3 receptor antagonist that blocks neurokinin B activation of kisspeptin/neurokinin B/dynorphin neurons to thereby modulate neuronal activity in the thermoregulatory center. Fezolinetant has been approved in many regions, including North America, Europe, Asia, and Australia for the treatment of vasomotor symptoms associated with menopause at a dose of 45 mg once daily (QD). The risk of potential QT prolongation for fezolinetant was assessed prior to the initiation of the phase 3 trials. A concentration–QTc (C–QTc) analysis was performed in accordance with recommendations from ICH E14 Guideline and utilized data from a phase 1 single and multiple ascending dose study, which tested single doses up to 900 mg and multiple daily doses up to 720 mg in healthy male and female participants. The fezolinetant C–QTc relationship indicated no clinically relevant QT prolongation at therapeutic or supra‐therapeutic doses of fezolinetant. Based on these modeling results as well as data from other clinical and non‐clinical studies, no thorough QT/QTc (TQT) study was required for fezolinetant. 10.1002/cpdd.1613 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/cpdd.1613 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_cpdd_1613 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Concentration–QTc Modeling to Support Clinical Development of Fezolinetant Jace C. Nielsen Masako Saito Xuegong Wang Megumi Iwai Graeme L. Fraser Steven Ramael Jiayin Huang Clinical Pharmacology in Drug Development Concentration–QTc Modeling to Support Clinical Development of Fezolinetant Jace C. Nielsen Masako Saito Xuegong Wang Megumi Iwai Graeme L. Fraser Steven Ramael Jiayin Huang Clinical Pharmacology in Drug Development Abstract Fezolinetant is a non‐hormonal, selective neurokinin‐3 receptor antagonist that blocks neurokinin B activation of kisspeptin/neurokinin B/dynorphin neurons to thereby modulate neuronal activity in the thermoregulatory center. Fezolinetant has been approved in many regions, including North America, Europe, Asia, and Australia for the treatment of vasomotor symptoms associated with menopause at a dose of 45 mg once daily (QD). The risk of potential QT prolongation for fezolinetant was assessed prior to the initiation of the phase 3 trials. A concentration–QTc (C–QTc) analysis was performed in accordance with recommendations from ICH E14 Guideline and utilized data from a phase 1 single and multiple ascending dose study, which tested single doses up to 900 mg and multiple daily doses up to 720 mg in healthy male and female participants. The fezolinetant C–QTc relationship indicated no clinically relevant QT prolongation at therapeutic or supra‐therapeutic doses of fezolinetant. Based on these modeling results as well as data from other clinical and non‐clinical studies, no thorough QT/QTc (TQT) study was required for fezolinetant. 10.1002/cpdd.1613 http://creativecommons.org/licenses/by/4.0/ |
| title | Concentration–QTc Modeling to Support Clinical Development of Fezolinetant |
| topic | Clinical Pharmacology in Drug Development |
| url | https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1613 |